Technical Brief · Liposomal NMN · NAD+ Precursor Delivery
Why Standard NMN Underperforms in B2B Formulas — and How Liposomal Delivery Lifts NAD+ Efficiency by 6x
Key takeaways
- The label claim is not the delivered dose. Free NMN is dephosphorylated and hydrolysed before absorption; what appears in circulation is largely nicotinamide rather than intact NMN.
- B2B failure is mechanical as well as biological. Hygroscopicity, compression behaviour, taste and shelf-time assay drift kill more NMN product lines at pilot scale than bioavailability debates do.
- Encapsulation efficiency is the only number that matters first. 85–95% encapsulation efficiency (EE) measured by NMR, with a dilution protocol for DLS particle sizing, separates a carrier from a claim.
- Loading percentage is mass arithmetic, not potency. A 10% powder needs 2,500 mg per serving to carry a 250 mg nominal dose; a 50% powder needs 500 mg. Format feasibility, not efficacy, is what this decides.
- Ask for nine documents, not a brochure. Assay, EE, size distribution, morphology, redox ratio, microbiology, heavy metals, moisture, change control.
What “6x efficiency” actually means — and what it does not
Most lipid-soluble nutrient marketing treats a multiple as a laboratory finding. Here it is not. EmerWell publishes an absorption window for standard NAD+ and NMN material of 10–20%, and a window of 60–90% for liposomal material produced on the EncapsWell™ platform. Dividing matching bounds gives the interval:
- Lower bound against lower bound: 60% ÷ 10% = 6.0x
- Upper bound against upper bound: 90% ÷ 20% = 4.5x
Any claim sharper than “4.5x–6x on these ranges” requires a measured dataset: a cross-over human study with matched dosing, a validated HPLC method for intact NMN, and AUC0–∞ reporting. If a supplier quotes 6x, 8x or 10x as a test result, ask which of those three they have. We do not have one for NMN specifically, and we say so below under What this comparison cannot show.
Figure 2. The derivation, printed in full so procurement can audit it. Ranges are EmerWell published specifications; the resulting 4.5x–6x interval is arithmetic on those ranges, not a bioequivalence study.
Why standard NMN underperforms in a real B2B formula
Nicotinamide mononucleotide is a phosphorylated dinucleotide ribose: water-soluble, ionised at gastric pH, and chemically unwilling to cross a lipid membrane on its own. Those three properties are the root of every downstream problem a formulator meets. The losses are sequential, which matters: each compartment removes part of the dose that the certificate of analysis measured in the powder.
Figure 1. The five compartments where a crystalline NMN dose is committed. Mechanism summaries follow published reviews of NAD+ precursor metabolism (references 1–3).
1. Before absorption: enzymatic and acid hydrolysis
Ectonucleotidases in saliva and along the luminal membrane begin cleaving the ribose-phosphate bond the moment a powder is wetted. In the stomach, pH 1.5–3.5 hydrolyses the bond between nicotinamide and ribose. Reviews of NMN and nicotinamide riboside metabolism describe the same pattern from the other direction: orally administered precursors are largely degraded in the gut, and the circulating signal is dominated by nicotinamide rather than the intact molecule [1][2]. Nothing about a tableted crystalline dose prevents this. It simply happens, and the percentage that happens at is exactly what the “standard” column of Figure 2 represents.
2. At absorption: dephosphorylation and first-pass conversion
Brush-border pyrophosphatases split NMN to nicotinamide riboside before uptake; the enterocyte then either re-synthesises it via nicotinamide riboside kinase or releases nicotinamide. Pyrophosphatase-mediated hydrolysis of ingested NAD+ at the brush border is documented in the same literature [2], and human intervention work confirms that oral NMN is “ultimately converted” before it raises blood NAD+ [3]. For a brand owner, the practical consequence is that two formulas with identical mg-per-serving can perform differently depending on how much survives this segment intact.
3. On the production line: six mechanical failure modes
This is where B2B projects actually stall. A material that passes an in-vitro bioavailability argument can still be unusable because it will not flow, will not compress, or will not taste acceptable in the target format.
Figure 4. Six failure modes a buyer normally discovers at pilot scale — after the ingredient has already been specified into the bill of materials.
| Failure mode | Capsule | Sachet / powder | Ready-to-drink | Gummy |
|---|---|---|---|---|
| Water uptake | Shell softening | Caking in the stick | Not applicable | Texture weep |
| Bitterness | Masked | Needs flavour load | Direct hit; drives sugar up | Direct hit |
| Thermal load | Minimal | Minimal | Pasteurisation step | 90 °C deposit |
| Compression | Weight variation | Not applicable | Not applicable | Not applicable |
| Dispersion / haze | Not applicable | Sediment | Halo and shelf complaints | Not applicable |
| Assay drift | Shortens dating | Shortens dating | Fastest drift | Fast drift |
4. Over shelf life: assay drift is a dating problem, not a potency rumour
Oxidation and hydrolysis continue in the finished pack. Moisture ingress, light, trace metals from tooling and headspace oxygen all accelerate it. The commercial expression of this is an expiry date shorter than the one priced into the launch plan, and a CoA that no longer describes the contents of the drum. A carrier does not make the molecule immortal; it removes most of the direct contact between the molecule and those stressors, which is why a liposomal grade is specified with an accelerated stability protocol rather than a promise.
How liposomal delivery changes each of those variables
A liposome is not a coating. It is a phospholipid bilayer enclosing an aqueous volume, and NMN — being hydrophilic — sits in that water phase rather than in the lipid tails. That single architectural fact changes six procurement variables simultaneously, which is why liposomal NMN is priced as an ingredient system rather than as a powder with a higher assay.
Figure 3. Anatomy of the carrier, with the six specification fields it adds. Schematic, not to scale.
- Acid exposure. The bilayer physically buffers the payload from gastric pH 1.5–3.5, so a smaller fraction of the dose is available to acid hydrolysis at all.
- Enzymatic access. Brush-border nucleotidases act on what they can touch. Encapsulated NMN is presented to them as vesicle interior rather than free solute.
- Hygroscopicity. The carrier, not the active, is the surface the environment meets; free-flow is a property of the vesicle powder.
- Taste. If the molecule does not reach the tongue, the bitterness never enters the sensory profile. For beverages this is the difference between a formula that needs 9 g of sweetener and one that needs 3.
- Process tolerance. The trade-off is honest and must be documented: vesicles are sensitive to high shear and high temperature, so the deposit and pasteurisation windows narrow even as the molecule is protected [5][6].
Where the encapsulation number is actually earned
Encapsulation efficiency is a process output, not a formulation intention. A supplier who cannot describe the thermal and sizing steps cannot defend the 85–95% they print. EmerWell's published process description runs: 99% purity NMN raw material, phospholipid film formation, a controlled thermal-homogenisation step held to 99.5% molecular integrity, vesicle sizing under DLS control, drying to a free-flowing powder, and release testing against a fixed analytical panel.
Figure 5. Process and release gates. The analytical panel — not the marketing copy — is what makes an encapsulation figure comparable between two suppliers.
Note that the panel mixes four different physical questions: how much active is present (HPLC), how big the vesicles are (DLS), how much active is actually carried (NMR), and whether the structure exists at all (TEM). A supplier quoting only the first has told you about the molecule, not the carrier. Reviews of liposomal processing make the same point from the opposite direction: stability of the vesicle — governed by size, lamellarity, cholesterol content and processing history — determines whether the delivery benefit survives to the finished pack [5][6].
Loading arithmetic: how much carrier a serving actually needs
Loading percentage is a mass ratio and is frequently mistaken for potency. Liposomal NMN is supplied at 10–70% NMN by weight from 99% purity raw material. To carry a 250 mg nominal NMN serving:
Figure 6. Mass balance only. This chart decides whether your dose fits the format; it says nothing about absorption.
- 10% loading → 2,500 mg powder per serving. Realistic in a bulk tin or a large sachet; impossible in a size-00 capsule (practical fill ceiling around 750–900 mg).
- 25% loading → 1,000 mg. Two capsules, or one sachet.
- 50% loading → 500 mg. The commercial default; this is the grade EmerWell recommends for premium finished products, and the basis of the published dosing example (100–300 mg of a 50% powder per serving, delivering 50–150 mg of active).
- 70% loading → 357 mg. Fits gummies and low-volume sachets, where excipient budget is tightest.
Standard versus liposomal NMN: the specification comparison
The table below is the version of the comparison that survives an audit, because every row names a method. Rows marked “not specified” for the standard grade are not a criticism of crystalline NMN — the field simply does not exist for an unencapsulated material.
| Attribute | Crystalline NMN | Liposomal NMN (EncapsWell™) | Method |
|---|---|---|---|
| Physical form | White crystalline powder, molecule only | Free-flowing powder; vesicles in a dried matrix | Visual, sensory panel |
| Active assay | 99% raw-material purity | 10–70% loading by weight | HPLC |
| Encapsulation efficiency | Not applicable | 85–95% | NMR (validated in-house) |
| Size reported | Particle-size distribution | Vesicle-size distribution with dilution protocol | DLS |
| Structure evidence | Not applicable | Micrograph retained per batch | TEM |
| Behaviour in cold water | Dissolves to a clear solution | Disperses to a stable, milky colloid | Standardised shake test |
| Taste threshold | Sour-bitter, detectable in water | Substantially masked by the carrier | Sensory panel vs. reference |
| Thermal window | Sensitive to heat and oxygen | Molecule protected; vesicle sensitive to shear and heat | Process validation |
| Dating basis | Lot history dependent | 24+ months, accelerated protocol | ICH Q1A(R2) style |
| Certification of the line | Supplier dependent | cGMP, ISO 22000, FSSC 22000 | Third-party audit |
What this comparison cannot show
Read this before you quote the 6x figure in a finished-product claim.
This article compares materials, methods and documents. It does not compare: absorption in humans, AUC or Cmax of intact NMN, blood NAD+ elevation between the two forms, or any health outcome. No peer-reviewed human head-to-head pharmacokinetic study of liposomal versus crystalline NMN was located while preparing this piece; the liposomal pharmacokinetic literature that does exist covers multivitamin and mineral systems, not NMN [4].
The absorption ranges come from EmerWell's own published specifications, so they are supplier statements rather than independent findings, and this article is written by that supplier. Whether a finished product may state anything about NAD+, energy or ageing depends on the ingredient's concentration in the pack, the permitted claim regime of the destination market and the brand's own substantiation file. That obligation sits with the brand, not with the ingredient supplier.
How to verify a liposomal NMN supplier in nine questions
If you take one thing from this article, take the question list. The format of the answer is a stronger signal than the number in it: “85–95%, NMR, method attached” is a specification, while “highly encapsulated” is an opinion.
Figure 7. Nine document gates. Rows 3 and 9 are the two most often skipped and the two that most often explain a failed pilot run.
When liposomal NMN is the wrong choice
A carrier is an engineering trade, and it is worth stating the boundary conditions before a procurement team builds a business case on the 4.5x–6x window. Liposomal NMN is usually the wrong answer when at least one of these is true:
- Your format deposits above 60 °C with high shear. Hot-fill gummies and aggressive homogenisation can disrupt the vesicle; encapsulation efficiency is the first casualty, and you pay a premium for a structure you have already destroyed.
- Your dose is already tiny and your cost-in-use is tight. If a 50–100 mg active dose at a low price point is the whole brief, a standard 99% crystalline grade compresses, dissolves and dates adequately.
- The product is a plain capsule with a taste barrier. Where the sensory argument disappears, two of the carrier's strongest benefits stop paying.
- You need a claim that liposomal NMN is clinically superior. As set out above, the human head-to-head evidence for NMN does not exist yet, so a carrier cannot carry a comparative claim in a regulated market.
| Primary driver | Standard crystalline NMN | Liposomal NMN |
|---|---|---|
| Lowest cost per mg active | Usually wins | Premium carrier cost |
| Ready-to-drink or flavoured sachet | Bitterness limits dose | Preferred: taste masked |
| High-dose longevity stack (500 mg+) | Fine in capsule | Preferred only if capsule count is the constraint |
| Long dating in a humid market | Weak moisture defence | Preferred, with barrier packaging |
| Gummy or hot-fill format | Thermal load on the molecule | Thermal load on the vesicle: validate first |
| Clinical comparative claim | Not supported | Not supported for NMN |
Cost model: price the carrier per delivered milligram
Buyers normally compare a liposomal grade against a standard grade on price per kilogram, which guarantees the wrong conclusion. Compare cost per delivered milligram of active in the finished serving instead:
- Cost per delivered gram = ingredient price per kg ÷ (loading % ÷ 100 × 1,000).
- A 99% crystalline grade at $X/kg delivers ~990 g of active per kg, so cost per delivered gram ≈ $X ÷ 990.
- A 50% liposomal grade at $Y/kg delivers 500 g of active per kg, so cost per delivered gram ≈ $Y ÷ 500 — before you count the excipients, flavour systems and line-time the carrier removes.
Because the carrier dilutes the active, the two effects multiply: cost per delivered gram rises by 1.98x for every 1.0x of price premium when you move from a 99% crystalline grade to a 50% liposomal grade (990 ÷ 500 = 1.98). A liposomal grade quoted at the same price per kg therefore already costs about twice as much per delivered gram, and at 1.5x per kg about three times as much. Holding the per-kg premium below roughly 1.5x is the practical test for a defensible business case; beyond that you are deliberately buying the carrier’s other properties, and the decision should be recorded as such.
Scaling from a line trial to a production contract
Once the grade is chosen, three questions decide whether the pilot survives contact with a real order book.
1. Sample-to-lot representativeness
Ask for the sample from the same lot that the CoA describes, and confirm that the encapsulation and size reports are for that lot rather than for a typical figure. A sample drawn from a development batch will mislead you on flow and dispersion.
2. Minimum order and pack geometry
EmerWell supplies from 1 kg sample packs to 25 kg commercial quantities. Confirm the drum liner, headspace and desiccant configuration at the volume you will actually order — carrier powders respond to the pack far more than crystalline powders do, and a 25 kg drum opened over three weeks behaves differently from a 1 kg foil pouch.
3. Change notification in writing
The most common cause of a failed re-run is a silently changed phospholipid source or a modified drying step. A supplier that will commit to written notification before shipment — covering source, process and specification — is worth more than one that quotes marginally lower. This is item 9 in Figure 7 for a reason.
Frequently asked questions
Is liposomal NMN really better than standard NMN?
For a B2B formula, the carrier reliably solves the handling problems — moisture uptake, flow, compression, bitterness, dispersion — and it reduces the molecule's direct exposure to gastric acid and brush-border enzymes. Whether it produces a better clinical result in a finished product is a separate question that no published human head-to-head study currently answers for NMN. Specify it for the delivery and the format; do not specify it on the strength of an outcome claim.
What does 6x bioavailability mean in practice?
On the ranges published here it means the liposomal window starts where the standard window ends: 60% against 10%. It is a range comparison, so the defensible statement is “4.5x to 6x on the published absorption windows”. Two suppliers quoting 6x may be quoting different methods, so the multiple is only meaningful alongside the assay method and the encapsulation-efficiency measurement.
How much liposomal NMN should go into a capsule?
Decide the nominal active per serving first, then divide by the loading. At 50% loading, 500 mg of ingredient carries 250 mg of NMN and fits a standard capsule. At 10% loading the same dose needs 2,500 mg, which does not. EmerWell's published dosing example for a 50% grade is 100–300 mg per serving, delivering 50–150 mg of active.
Can liposomal NMN be used in beverages and powders?
Yes, with two constraints. The dispersion is colloidal, so a defined addition sequence and moderate mixing energy are required; and because vesicles are sensitive to shear and heat, pasteurisation and hot-fill windows must be validated on your own line before scale-up. Cold-water dispersibility is specified for the powder, which is the practical reason brands choose it for ready-to-drink formats.
What documentation should a liposomal NMN supplier provide?
Nine items per lot: HPLC assay against the declared loading; NMR-derived encapsulation efficiency; DLS vesicle-size distribution with the dilution protocol; a TEM micrograph; the reduced-to-oxidised ratio where the molecule is redox-active; numeric microbiology (TAMC and yeast/mould); heavy metals for lead, arsenic, cadmium and mercury; moisture by loss on drying with the observed value; and a written change-control commitment. If item 9 is absent, every earlier number becomes provisional.
Does encapsulation change the NMN content on the certificate of analysis?
It changes what the number describes. An assay reports how much NMN is in the sample; it does not report how much of that NMN is inside a vesicle. Two powders can both read 50% and carry very different delivered fractions, which is exactly why encapsulation efficiency is a separate, orthogonal measurement.
What shelf life should I specify for liposomal NMN powder?
Ask for the protocol, not the month count. A 24-month claim backed by an ICH Q1A(R2)-style accelerated programme is auditable; a 24-month claim with no conditions is a wish. Specify storage temperature, humidity, headspace and the packaging film, then re-test at the dating horizon in your own finished format.
Is liposomal NMN suitable for vegan formulations?
It depends entirely on the phospholipid source. Sunflower- and soy-derived phospholipids are vegan-compatible; bovine and marine sources are not, and egg-derived lecithin introduces an allergen declaration. Confirm the source in writing, since it affects labelling in the EU, UK and US simultaneously.
Sources and further reading
- Nicotinamide Mononucleotide Supplementation: Understanding Metabolic Variability and Clinical Implications — Nutrients review, PMC11205942. pmc.ncbi.nlm.nih.gov/articles/PMC11205942
- NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health — review, PMC10240123. pmc.ncbi.nlm.nih.gov/articles/PMC10240123
- Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood NAD+ Levels in Healthy Subjects — PMC9036060. pmc.ncbi.nlm.nih.gov/articles/PMC9036060
- Pharmacokinetic Analyses of Liposomal and Non-Liposomal Multivitamin/Mineral Formulations — PMC10347199. pmc.ncbi.nlm.nih.gov/articles/PMC10347199
- Liposomal Encapsulation in Food Systems: A Review of Formulation, Processing, and Applications — PMC12321603. pmc.ncbi.nlm.nih.gov/articles/PMC12321603
- An Overview of Liposomal Nano-Encapsulation Techniques and Its Applications in Food and Nutraceutical — PMC7447741. pmc.ncbi.nlm.nih.gov/articles/PMC7447741
- Stability testing reference framework: ICH Q1A(R2), Stability Testing of New Drug Substances and Products (guideline title cited for method structure; obtain the current PDF from the ICH database).
Related EmerWell technical pages
- Liposomal NMN Powder — product specification
- Liposomal NAD+ Powder — product specification
- How does liposomal encapsulation improve NMN absorption?
- How is liposomal NMN powder made: a process guide
- What to check in a liposomal NMN powder CoA
- Liposomal NMN powder: stability testing and storage
- Liposomal NAD+ powder vs NMN: which is better?
- Best liposomal NMN powder supplier: 7 checks to make
- Which form of NMN is best: liposomal powder, sublingual or capsule
- Liposomal NMN powder certifications for B2B sourcing
Written by the EmerWell Formulation Science Team. The team works on lipid-based delivery, vesicle characterisation and scale-up for supplement brands and contract manufacturers. Technical review against current batch documentation by the EmerWell QA group.
Disclosure: EmerWell manufactures and sells the liposomal ingredients discussed here. The comparison is written for technical buyers and every number in this article is traceable to a published specification, a named test method or one of the sources listed above.
Specify the carrier, not the claim
Send the format you are developing — capsule, sachet, gummy or ready-to-drink — together with your target active per serving. We will return the loading grade that fits, the batch CoA, the encapsulation-efficiency report, the vesicle-size distribution with its dilution protocol, and a sample for your line trial.